invasive fungal disease

Refractory fungal infection: Three case reports highlighting good practice

mycolabadmin

This case series examines three patients with serious fungal infections that did not respond well to standard antifungal treatments. The cases demonstrate how fungi can develop resistance to common antifungal drugs like azoles, making infections harder to treat. The authors emphasize that accurate identification of the fungus, testing its sensitivity to drugs, monitoring drug levels in the blood, and careful use of antifungal medications are essential for successfully treating these difficult infections.

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19 infection, a fungal marker called beta-D-glucan (BDG) in the blood can predict patient survival even without a diagnosed fungal infection. Researchers found that COVID-19 patients with high BDG levels had a 91% death rate if not treated with antifungal drugs, but this dropped to 50% when antifungal therapy was given. The high BDG levels trigger a strong inflammatory response in the body that worsens disease severity, making BDG a valuable warning sign for doctors treating critically ill COVID-19 patients.

Antifungal stewardship in the UK: where are we now?

mycolabadmin

Fungal infections are becoming more common and dangerous because some fungi are developing resistance to antifungal medicines. UK hospitals struggle to manage these infections due to lack of funding, staffing, and limited access to fungal testing services. The paper recommends creating regional fungal expertise centers and setting national standards to improve how antifungal medications are used and monitored across the country.

Invasive Fungal Disease is Rare in Multiple Myeloma Patients Treated with BCMA CAR-T Therapy

mycolabadmin

Researchers studied 234 multiple myeloma patients who received a cutting-edge cancer treatment called BCMA CAR-T therapy. While this therapy can cause serious side effects related to immune system activation, the study found that dangerous fungal infections were surprisingly rare, occurring in only 1.7% of patients. However, when fungal infections did occur in these patients, they tended to be severe and life-threatening, highlighting the need for careful monitoring of high-risk patients.

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This review examined how well liposomal amphotericin B (a fungal medication) works to prevent serious fungal infections in children. Researchers looked at 20 studies involving over 2000 children and found that about 7% still developed fungal infections despite the medication, with common side effects being low potassium levels and liver problems. The main finding is that doctors use this medication in very different ways, and we need better research to figure out the best dosing strategy for children.

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This study reviews how a fungal medication called liposomal amphotericin B is used to prevent serious fungal infections in children with weakened immune systems, particularly those with blood cancers or who have had bone marrow transplants. The researchers found that this medicine prevents infections in about 93% of children, though it does cause side effects like low potassium levels in about 23% of patients. However, the study shows that current use of this medicine is quite varied and more high-quality research is needed to determine the best dosing approach.

Shared Vision for Improving Outcomes for Serious Fungal Diseases: Report of a Patient, Caregiver, and Clinician Summit

mycolabadmin

Patients with serious fungal infections face significant challenges including long delays before diagnosis, substantial emotional and financial burden, and lasting effects on quality of life. A summit brought together patients, their caregivers, and fungal disease experts to share experiences and identify priorities for improving care. The group identified needs for better diagnostic tools, new treatments, improved medical education about fungal diseases, and patient support programs to help future patients and their families navigate fungal infections more effectively.

COVID-19-associated Pulmonary Aspergillosis in Mechanically Ventilated Patients at 7 US Hospitals: Epidemiology and Estimated Likelihood of Invasive Pulmonary Aspergillosis—Results of the Prospective MSG-017 Study

mycolabadmin

A fungal infection caused by Aspergillus commonly occurs in COVID-19 patients on ventilators, affecting about 7% of cases. The study found that having this infection was linked to high death rates, but it was unclear whether the fungal infection itself or the severe COVID-19 caused the deaths. Single positive test results for the fungus are not reliable for diagnosis, and antifungal drugs did not improve survival rates.

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19, patients in intensive care sometimes develop dangerous fungal infections. Doctors use a blood test to measure a fungal marker called BDG to help diagnose these infections. This study found that even without confirmed fungal infection, high BDG levels predicted who would not survive, but giving antifungal medications improved survival even without proven infection.

Research Topic: invasive fungal disease